1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Tiziano Frateschi
Tiziano Frateschi
Articles (2114)  | Author's Website |

Vanguard Health Care Fund's Largest Sales of the 3rd Quarter

Fund trims Cigna and Eli Lilly holdings, sells Envision Healthcare

The Vanguard Health Care Fund (Trades, Portfolio), which invests primarily in health care-related companies in order to achieve long-term capital appreciation, sold shares of the following stocks during the third quarter.

The fund reduced its Cigna Corp. (NYSE:CI) position by 27.90%. The trade had an impact of -0.41% on the portfolio.

c6aba2e0-e194-11e8-bfeb-65eb3f28a204.png

The company, which provides medical, dental and health insurance products, has a market cap of $52.48 billion and an enterprise value of $53.4 billion.

GuruFocus gives the company a profitability and growth rating of 4 out of 10. The return on equity of 19.06% and return on assets of 4.14% are underperforming 50% of companies in the Global Health Care Plans industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 0.96 is below the industry median of 1.15.

The company's largest shareholder among the gurus is Dodge & Cox with 4.28% of outstanding shares, followed by Barrow, Hanley, Mewhinney & Strauss with 0.81%, Larry Robbins (Trades, Portfolio) with 0.69% and Jim Simons (Trades, Portfolio)' Renaissance Technologies with 0.32%.

The firm trimmed its Eli Lilly and Co. (NYSE:LLY) stake by 7.32%. The trade had an impact of -0.34% on the portfolio.

4df39600-e195-11e8-a02c-b1bcca13ee0a.png

The company, which develops human and animal pharmaceutical products, has a market cap of $118.29 billion and an enterprise value of $123.66 billion.

GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of -1.08% and return on assets of -0.33% are underperforming 66% of companies in the Global Drug Manufacturers - Major industry. Its financial strength is rated of 6 out of 10. The cash-debt ratio of 0.57 is below the industry median of 2.03.

The largest shareholder of the company is PRIMECAP Management (Trades, Portfolio) with 5.13% of outstanding shares, followed by Ken Fisher (Trades, Portfolio) with 0.35% and Sarah Ketterer (Trades, Portfolio) with 0.25%.

Vanguard exited its Envision Healthcare Corp. (NYSE:EVHC) holding. The trade had an impact of -0.29% on the portfolio.

a4e01ad0-e195-11e8-acf7-07c1f4e421f3.png

The company, which supplies health care services to its clients, has a market cap of $5.58 billion and an enterprise value of $10.27 billion.

GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of -29.05% and return on assets of -11.24% are underperforming 79% of companies in the Global Medical Care industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.13 is below the industry median of 0.28.

Lee Ainslie (Trades, Portfolio) is the largest guru shareholder of the company with 5.56% of outstanding shares, followed by Joel Greenblatt (Trades, Portfolio) with 0.56%, Mario Gabelli (Trades, Portfolio) with 0.13% and George Soros (Trades, Portfolio) with 0.12%.

The health care fund curbed its Medtronic PLC (NYSE:MDT) stake by 9.84%. The trade impacted the portfolio by -0.28%.

0cdeb580-e196-11e8-a9f9-97b7436e6569.png

The medical technology company has a market cap of $123.96 billion and an enterprise value of $138.29 billion.

GuruFocus gives the company a profitability and growth rating of 9 out of 10. The return on equity of 6.24% and return on assets of 3.35% are outperforming 59% of companies in the Global Medical Devices industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.44 is below the industry median of 2.32.

The largest guru shareholder of the company is Dodge & Cox with 1.33% of outstanding shares, followed by the Barrow, Hanley, Mewhinney & Strauss with 1.08%, PRIMECAP Management with 0.6% and Pioneer Investments (TradesPortfolio) with 0.4%.

The Boston Scientific Corp. (NYSE:BSX) stake was trimmed by 10.42%, impacting the portfolio by -0.27%.

91cdfcc0-e196-11e8-8b6d-ef76926c1f89.png

The company, which markets its devices to health care professionals and institutions, has a market cap of $50.31 billion and an enterprise value of $56.77 billion.

GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 8.89% and return on assets of 3.46% are outperforming 51% of companies in the Global Medical Devices industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.03 is below the industry median of 2.32.

Vanguard is the company's largest shareholder among the gurus with 2.27% of outstanding shares, followed by Jana Partners (Trades, Portfolio) with 0.23%, Diamond Hill Capital (Trades, Portfolio) with 0.21% and Pioneer with 0.19%.

The Illumina Inc. (NASDAQ:ILMN) holding was reduced by 35.13%. The trade impacted the portfolio by -0.27%.

75ee7070-e197-11e8-aa12-f750447d2f5a.png

The company, which manufactures DNA sequencing technology, has a market cap of $47.65 billion and an enterprise value of $44.09 billion.

GuruFocus gives the company a profitability and growth rating of 9 out of 10. The return on equity of 22.25% and return on assets of 12.02% are outperforming 92% of companies in the Global Diagnostics and Research industry. Its financial strength is rated 7 out of 10. The cash-debt ratio of 1.72 is below the industry median of 3.52.

The largest guru shareholder of the company is Frank Sands (Trades, Portfolio) with 2.91% of outstanding shares, followed by Spiros Segalas (Trades, Portfolio) with 1.08%, PRIMECAP Management with 0.77% and Andreas Halvorsen (Trades, Portfolio) with 0.34%.

The Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stake was reduced 8.94%, impacting the portfolio by -0.25%.

d45664e0-e197-11e8-af3f-edf691a39ea5.png

The pharmaceutical company has a market cap of $44.62 billion and an enterprise value of $42.67 billion.

GuruFocus gives the company a profitability and growth rating of 6 out of 10. The return on equity of 27.38% and return on assets of 16.46% are outperforming 93% of companies in the Global Biotechnology industry. Its financial strength is rated 7 out of 10. The cash-debt ratio of 5.20 is below the industry median of 64.02.

Vanguard is the company's largest shareholder among the gurus with 2.62% of outstanding shares, followed by Simons‘ firm with 1.58% and Segalas with 0.77%.

Disclosure: I do not own any stocks mentioned in this article.

Read more here:

About the author:

Tiziano Frateschi
You can read about me on www.theextraincome.info, which gives suggestions on position trading.

Visit Tiziano Frateschi's Website


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Tiziano Frateschi


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK